Thanks for visiting Scientific Computing World.

You're trying to access an editorial feature that is only available to logged in, registered users of Scientific Computing World. Registering is completely free, so why not sign up with us?

By registering, as well as being able to browse all content on the site without further interruption, you'll also have the option to receive our magazine (multiple times a year) and our email newsletters.

Aptevo Therapeutics streamlines cancer immunotherapy research

Share this on social media:

Seattle-based Aptevo Therapeutics, a clinical-stage biotechnology company, is using Genedata Biologics software to accelerate cancer research. Aptevo will use the Genedata platform to expand their pipeline of novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation.

‘To increase the throughput of our bispecific discovery program we needed a flexible E2E workflow system that could support our proprietary discovery technologies and ADAPTIR protein therapeutic platform,’ said Dr Peter Pavlik, director of Molecular Biology and Protein Engineering Research at Aptevo. ‘We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.’

‘We appreciate Genedata Biologics’ flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution,’ said William Benjamin, IT Director at Aptevo. ‘As an established, off-the-shelf product, Genedata Biologics could be deployed across our organization with minimal customization. Also, this cloud-based solution was particularly appealing because of the rapid implementation it offered. We are very pleased with Genedata’s strong commitment to service and technical support and look forward to a long and productive partnership.’

‘We are excited to work with Aptevo, an innovative leader in the development of novel immunotherapies. This partnership illustrates how Genedata works with future industry leaders who need a platform for scale up and automation of their R&D operations as they grow as an organisation,’ said Dr Othmar Pfannes, CEO of Genedata. ‘We are committed to helping our partners – both large and small – be innovative and at the same time efficient.’

Since its first release in 2011, Genedata Biologics has been rapidly adopted by the majority of the world’s leading biopharmaceutical companies, as well as emerging speciality biotech companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.

Company: